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Amyotrophic lateral sclerosis and frontotemporal dementia are overlapping diseases in which MRI reveals brain structural changes
in advance of symptom onset. Recapitulating these changes in preclinical models would help to improve our understanding of the
molecular causes underlying regionally selective brain atrophy in early disease. We therefore investigated the translational potential
of the TDP-43Q331K knock-in mouse model of amyotrophic lateral sclerosis-frontotemporal dementia using MRI. We performed
in vivo MRI of TDP-43Q331K knock-in mice. Regions of significant volume change were chosen for post-mortem brain tissue anal-
yses. Ex vivo computed tomography was performed to investigate skull shape. Parvalbumin neuron density was quantified in post-
mortem amyotrophic lateral sclerosis frontal cortex. Adult mutants demonstrated parenchymal volume reductions affecting the
frontal lobe and entorhinal cortex in a manner reminiscent of amyotrophic lateral sclerosis-frontotemporal dementia. Subcortical,
cerebellar and brain stem regions were also affected in line with observations in pre-symptomatic carriers of mutations in C9orf72,
the commonest genetic cause of both amyotrophic lateral sclerosis and frontotemporal dementia. Volume loss was also observed in
the dentate gyrus of the hippocampus, along with ventricular enlargement. Immunohistochemistry revealed reduced parvalbumin
interneurons as a potential cellular correlate of MRI changes in mutant mice. By contrast, microglia was in a disease activated state
even in the absence of brain volume loss. A reduction in immature neurons was found in the dentate gyrus, indicative of impaired
adult neurogenesis, while a paucity of parvalbumin interneurons in P14 mutant mice suggests that TDP-43Q331K disrupts neurode-
velopment. Computerized tomography imaging showed altered skull morphology in mutants, further suggesting a role for TDP-
43Q331K in development. Finally, analysis of human post-mortem brains confirmed a paucity of parvalbumin interneurons in the
prefrontal cortex in sporadic amyotrophic lateral sclerosis and amyotrophic lateral sclerosis linked to C9orf72 mutations. Regional
brain MRI changes seen in human amyotrophic lateral sclerosis-frontotemporal dementia are recapitulated in TDP-43Q331K knock-
in mice. By marrying in vivo imaging with targeted histology, we can unravel cellular and molecular processes underlying selective
brain vulnerability in human disease. As well as helping to understand the earliest causes of disease, our MRI and histological
markers will be valuable in assessing the efficacy of putative therapeutics in TDP-43Q331K knock-in mice.
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DAB ¼3,30-diaminobenzidine; DAM ¼disease-associated microglia; DCX ¼doublecortin; FTD ¼frontotemporal dementia;
FWE ¼family-wise error; Iba-1 ¼ionized calcium-binding adapter molecule 1; MND ¼motor neurone disease; PV
¼parvalbumin; ROI ¼region of interest; RT ¼room temperature; SOM ¼somatostatin; TBM ¼tensor-based morphometry;
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Introduction
Amyotrophic lateral sclerosis (ALS) and frontotemporal de-
mentia (FTD) exist on a clinicopathological and genetic dis-
ease spectrum (ALS-FTD). The loss of upper and lower
motor neurons in ALS leads to paralysis, while FTD is
characterized by frontal and temporal lobar degeneration
causing executive dysfunction, language impairment and be-
havioural changes.1 From the point at which patients with
ALS-FTD describe their first symptoms the decline is often
rapid, with death ensuing within 3–5 years. However, it is
increasingly apparent that patients can have seemingly
asymptomatic prodromes that can extend for decades prior
to clinical onset. This conclusion arises from studies using
sensitive magnetic resonance imaging (MRI) methods, which
have detected subtle deviations in brain structure or func-
tion in pre-symptomatic carriers of ALS-FTD-linked gene
mutations.2–5 It follows that combining genetics with non-
invasive imaging is a powerful approach to identify bio-
markers of early disease.6 This is invaluable to enable early
diagnosis and early therapeutic intervention to delay onset,
slow progression or even prevent disease altogether, thereby
providing the greatest possible benefit to patients.
Almost all patients with ALS and half of FTD cases are
characterized by pathological processing of the RNA-bind-
ing protein TDP-43.7–9 Mutations in TARDBP, which enc-
odes TDP-43, are also linked with ALS and FTD.10,11
These observations indicate key but undefined roles for
TDP-43 in the pathogenesis of ALS-FTD. To elucidate mo-
lecular processes underlying the genesis of ALS-FTD it
would be ideal to spatially resolve early brain changes
in vivo and correlate regional atrophy with histological
data in preclinical TDP-43 models. Such an approach
promises to identify cross-species biomarkers of disease,
with the potential to facilitate translational research. In
vivo brain imaging, for example, offers the potential to
directly correlate results from animal disease models with
human imaging data. However, few such studies have
been conducted in ALS-FTD models of disease, and these
have not utilized an unbiased approach to identify affected
brain regions of interest for further study.
Ideally, preclinical models should accurately reflect the
human genetic state to ensure that observations are not due
to artefacts caused by exogenous expression of transgenes. In
the case of TDP-43, it is also important to ensure ubiquitous
expression including throughout development.12 These criteria
are fulfilled by the TDP-43Q331K knock-in mouse, which har-
bours a single human-equivalent point mutation in the en-
dogenous mouse Tardbp gene.13 We previously showed that
this mutation causes a gain of function due to a loss of
TDP-43 autoregulation, which leads to progressive behav-
ioural features of FTD. Here, using in vivo MRI, ex vivo
computed tomography (CT) and histology of TDP-43Q331K
knock-in mice, we make a significant translational step
using this model. Firstly, we find a striking recapitulation
of regional brain atrophy as seen in human ALS-FTD. We
then use these MRI results to guide our histological studies,
which implicate interneurons, microglia, impaired neurogen-
esis and aberrant neurodevelopment in early stage disease.
Finally, we validate our interneuron observation using hist-
ology of human post-mortem brain tissues.
Materials and methods
Mouse breeding and maintenance
All animal experiments were performed under the UK
Animal (Scientific Procedures) Act 1986 Amendment
Regulations 2012 on Project Licences P023CC39A and
P35785FD7. The creation of the TDP-43Q331K knock-in
mouse was previously described.13 For the current study,
heterozygous (TDP-43Q331K/þ) mice were intercrossed
to generate TDP-43Q331K/Q331K, TDP-43Q331K/þ and wild-
type offspring. All mice were bred on a C57Bl/6J
background. Genotyping for the Q331K mutation was
performed as described previously.13 Animals were
group-housed in individually ventilated Tecniplast cages
within a clean facility. Individual cages contained envir-
onmental enrichment items and group sizes of two to five
mice were routinely maintained under a 12 h light/dark
cycle with ad libitum access to food and water. Given
that we previously found that males demonstrated more
marked phenotypes than females,13 we focussed our at-
tention on male mice in the current study.
Structural magnetic resonance
imaging
In vivo MRI was performed on 7-month-old (28–
32 weeks, 27.3–38.6 g) male mice (10 TDP-43Q331K/þ, 10
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TDP-43Q331K/Q331K and 15 wild-type littermates) using a
9.4 T horizontal bore Bruker BioSpec 94/20 scanner
(Bruker BioSpin, Ettlingen, Germany). An 86-mm volume
resonator and a 2 2 phased array surface coil were
used for RF transmission and reception, respectively.
During scanning, the mice were anaesthetized with
2–2.5% isoflurane. Their respiration rate and core
temperature were monitored and maintained at
60–80 breaths/min and 37 6 0.5C (SA Instruments, Inc.).
3D T1-weighted images were acquired using an
MPRAGE sequence with the following parameters: echo
time ¼ 3.8 ms, repetition time ¼ 9.66 ms, inversion
time ¼ 1300 ms, flip angle ¼ 10, segment repetition
time ¼ 3500 ms, 4 segments, 4 averages, field of view ¼
16 mm 16 mm 8 mm, matrix ¼ 128 128 64, scan
time ¼ 40 min. One wild-type and one TDP-43Q331K/þ
mouse were excluded due to poor image quality.
Visual inspection of the MR images revealed that ven-
tricular enlargement is a clear phenotype of homozygous
TDP-43Q331K/Q331K mutants. To quantify this using
MATLAB (MathWorks, Natick, MA, USA) and FSL
(FMRIB, Oxford, UK), the ventricles of each mouse were
semi-automatically segmented through a combination of
thresholding, morphological operations and manual edit-
ing if necessary. The volumes of these ventricle masks
were compared across genotypes.
Tensor-based morphometry (TBM) was performed to
assess the effects of mutant TDP-43Q331K on local brain
volume. First, N4 bias field correction was applied to the
MPRAGE images to remove the signal inhomogeneity
arising from the surface coil’s non-uniform sensitivity
profile. Then, a study-specific template was created using
ANTs (antsMultivariateTemplateConstruction2.sh). All
subjects were registered to the template via sequential
rigid, affine and non-linear SyN transforms
(antsRegistration). The MPRAGE images and ventricle
masks were given equal weight in the registration to im-
prove the normalization of the largely varying ventricle
sizes. Two TDP-43Q331K/Q331K mice with frank hydro-
cephalus were excluded from further analysis because
their ventricles could not be satisfactorily normalized to
the template.
Jacobian determinant maps of the resultant deformation
fields were computed and log-transformed. To compare
local volume differences between mutant and wild-type
mice, voxel-based nonparametric statistics were performed
on the log-transformed Jacobian determinant maps using
FSL randomize [5000 permutations, threshold-free cluster
enhancement, family-wise error (FWE) correction]. An
ANOVA was performed, followed by pair-wise compari-
sons between genotypes. We did not correct for global
scaling as total brain volumes (i.e. brain plus ventricles)
did not differ between genotypes.
The DSURQE mouse brain atlas (The Mouse Imaging
Centre, Toronto)14 was similarly registered to the study-
specific template for region of interest (ROI) analysis. For
each mouse, ROI volumes were calculated by summing
the Jacobian determinant values within each ROI.
MATLAB was used to perform two-tailed Mann–
Whitney U-tests to compare ROI volumes between each
pair of groups, controlling for false discovery rate using




Following MRI, mice were culled by asphyxiation with
CO2 followed by cervical dislocation and tissue extrac-
tion. The brains were immersion fixed in 4% paraformal-
dehyde at 4C for 24–48 h, washed in phosphate
buffered saline (PBS) and cryoprotected in 30% sucrose
in PBS at 4C for 72 h. The tissues were then embedded
in M1 matrix in a silicon mould, frozen on dry ice, sec-
tioned at 35 lm thickness on a cryostat (Leica) and
stored in cyroprotectant (25% ethylene glycol, 30% gly-
cerol) at 20C. Tissue sections were then immunos-
tained as follows (a list of the antibodies used is
provided in Supplementary Table 1).
Immunostaining
For parvalbumin (PV) immunofluorescent staining cryo-
protected sections were washed in PBS for 20 min, 0.2%
TritonX-100/PBS for 10 min and blocked in 5% normal
goat serum (NGS)/0.2% TritonX-100/PBS for 1 h at
room temperature (RT). Sections were incubated over-
night at 4C with primary anti-PV antibody diluted in
blocking buffer, washed in 0.2% TritonX-100/PBS, then
incubated for 2 h at RT with secondary antibody diluted
in blocking buffer, then washed in 0.2% TritonX-100/
PBS. Sections were subsequently washed in PBS and
mounted onto Superfrost Plus slides (VWR, France) with
Vectashield HardSet with 40,6-diamidino-2-phenylindole
(DAPI) (Vector Laboratories, USA).
We assessed microglia by staining for ionized calcium-
binding adapter molecule 1 (Iba-1), which is elevated in
activated microglia, and transmembrane protein 119
(Tmem119). Tmem119 is poorly understood but is
expressed on the cell surface of brain resident microglia,
but not blood-derived macrophages15 and has roles in
myoblast differentiation. Although its functions in micro-
glia remain unclear the expression of Tmem119 protein
has been shown to be reduced in disease-associated
microglia (DAM).16–18 For Iba-1 and Tmem119 co-im-
munofluorescent staining, antigen retrieval was first per-
formed by heating the samples for 20 min at 80C in
sodium citrate buffer (pH 6.5). Sections were cooled to
RT, washed in distilled water, and blocked and permea-
bilized in a solution containing 5% bovine serum albu-
min, 0.5% Triton X-100 for 1 h at RT. Slides were
incubated with primary antibody (goat anti-Iba1, Abcam,
ab5076, 1:500) for 4C overnight in 2-fold-diluted block-
ing buffer. Secondary antibody (donkey anti-goat, Alexa








s/article/3/2/fcab114/6286948 by guest on 04 O
ctober 2021
Fluor 488, 1:500) was applied for 1 h at RT. Sections
were then washed and blocked again as above and incu-
bated with primary antibody (rabbit anti-Tmem119,
Abcam, ab209064, 1:1000) for 4C overnight. Secondary
antibodies were applied for 1 h at RT (goat anti-rabbit,
Alexa Fluor 568, 1:500). Sections were counterstained
and mounted with Vectashield HardSet with DAPI
(Vector Laboratories, USA).
For DAB (3,30-Diaminobenzidine) immunohistochemis-
try, sections were washed in 0.1 M phosphate buffered
saline (PBS) and 0.1 M PBS-Tween (PBS-T). Endogenous
peroxidases were quenched by washing in PBS plus 1.5%
H2O2 for 20 min. Sections were washed again. Antigen
retrieval was performed where needed (i.e. for myelin
basic protein and Ki67 staining) in sodium citrate at
70C for 1 h. Sections were blocked in 5% normal goat
serum in PBS-T for 1 h, washed and then incubated over-
night at 4C with primary antibody in PBS-T and 2%
normal goat serum solution. Sections were washed again
prior to incubation with biotinylated secondary antibody
in PBS-T for 70 min. Sections were washed and incubated
in ABC solution (Vectastain ABC Elite, PK-6000, Vector
Laboratories, USA) for 90 min in the dark, then washed
twice more in PBS, and incubated with 0.1 M sodium
acetate pH 6 for 10 min. Immunoreactivity was developed
in DAB solution followed by two washes in PBS. Sections
were mounted and allowed to dry overnight before being
dehydrated and de-lipidized in increasing concentrations
of ethanol. Sections were incubated in Histoclear (2  3
min; National Diagnostics, USA) and cover-slipped with
mounting medium (Sigma Aldrich, UK).
Image analyses
For adult mouse immunostaining, images were captured
using an Olympus Whole Slide Scanner (VS120,
Olympus, Japan) with a 20 objective. Z-stacks of 5
layers were obtained at 20 magnification throughout
each section. Images were auto-stitched using Olyvia soft-
ware (Olympus). Images were analysed using Visiopharm
image analysis software (Hoersholm, Denmark) blind to
genotype. Anatomically equivalent sections were selected
from 4 to 6 mice of each genotype. ROIs were manually
drawn in each chosen section according to the Allen
mouse brain atlas (Allen Institute for Brain Science). Each
ROI extended through 3–6 sections depending on its size.
Each marker was measured using a custom Visiopharm
application via threshold classification and post process-
ing changes. The number of any particular cellular sub-
type per tissue area (‘cell density’), and the proportion of
an area positive for any marker (‘percentage area’), were
calculated. The measurements in all sections for each
ROI were summed for each mouse (density ¼ total cell
number/total tissue area; percentage area ¼ total marker-
positive area/total tissue area).
For quantification of PVþ interneurons in P14 mouse
hippocampi, cells were manually quantified (30 mm con-
focal z-stacks, Leica TCS SP5) from six anatomically
equivalent sections per animal within a given region using
Fiji (ImageJ). Watershed algorithm was used to define the
ROI and DAPIþ cells quantified with the parameters—ra-
dius: 0.5; min level: 90–127; max level: 127–192; erode/
dilate iterations: 0 in binary images. Mean pixel inten-
sities were checked for accuracy by redirecting measure-
ments to the original image for overlay with DAPI. The
fold change of immunostaining in all animals for each
ROI was calculated relative to the mean value of wild-
type controls.
Ex vivo micro-CT imaging and data
analysis
For micro-CT, 24-month-old male mice were perfused
with 2% paraformaldehyde, and heads were processed as
previously described.19 Heads were scanned using a
Scanco mCT50 micro-CT scanner (Scanco, Brüttisellen,
Switzerland). The specimens were immobilized in 19 mm
scanning tubes using cotton gauze and scanned to pro-
duce 20 mm voxel size volumes, using X-ray settings of
70 kVp, 114 mA and a 0.5 mm aluminium filter to at-
tenuate harder X-rays. The scans were automatically
scaled at reconstruction using the calibration object pro-
vided by the CT manufacturer, consisting of five rods of
hydroxyapatite at concentrations of 0 to 790 mg/cm3,
and the absorption values expressed in Hounsfield units.
For CT image analysis, 53 landmarks of the skull were
obtained by reconstructing a 3D surface of the micro-CT
images using Microview software by Parallax Innovations
(http://www.parallax-innovations.com/microview.html, last
accessed 7 June 2021) followed by genotype-blinded
manual placement and orthogonal-view cross-checking.
The MorphoJ software package20 was used to apply
Procrustes superimposition to landmarks for alignment
after which shape variation was visualized through princi-
pal component analysis. Procrustes Distance Multiple
Permutations test (1000 iterations) was used to quantify
the significance of shape differences between genotypes.
Size differences were compared by measuring the centroid
size (square root of the sum of the squared distances
from each landmark to the centroid) and significance
measured via an unpaired t-test. Videos were generated
by taking one representative homozygous mutant and
one representative wild-type mouse and using a pipeline
as previously described21 to morph between them.
Human tissue studies
Patient details
All patients had clinical and electrophysiological evidence
of combined upper and lower motor neuron dysfunction
and fulfilled the revised El Escorial criteria for a diagno-
sis of ALS.22 Patients were recruited through the Scottish
Motor Neurone Disease Register and data collected in
the CARE-MND database (Clinical Audit Research and
Evaluation—motor neurone disease). Ethical approval for
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this register was obtained from Scotland A Research
Ethics Committee 10/MRE00/78 and 15/SS/0216. All clin-
ical data were subsequently extracted from the CARE-
MND database.
Patients gave pre-mortem consent for brain and spinal
cord donation. All tissue retrievals were in line with the
Human Tissue (Scotland) Act, and all procedures have
been approved by a national ethics committee. Use of
human tissue for post-mortem studies has been reviewed
and approved by the Sudden Death Brain Bank ethics
committee and the ACCORD medical research ethics
committee, AMREC (ACCORD is the Academic and
Clinical Central Office for Research and Development, a
joint office of the University of Edinburgh and NHS
Lothian). Details of all donors used in this study (ages,
sex and C9orf72 mutation status) with means for each
group can be found in Supplementary Tables 2 and 3.
Neuropathology
Fresh post-mortem tissue blocks of human brain were
fixed in 10% formalin for a minimum of 24 h. Tissue
was dehydrated in an ascending alcohol series (70–
100%), followed by three xylene washes, all for 4 h each.
Next, three paraffin waxing stages (5 h each) were per-
formed to ensure full penetration of the embedding wax
and the blocks were cooled. Tissue sections were cut on
a Leica microtome at 4 lm and collected on glass slides.
All sections were dried at 40C for at least 24 h before
staining. Immunohistochemistry was performed using
standard protocols, enhanced using a sensitive avidin/bio-
tin kit (VECTASTAIN ABC Elite) and visualized using
DAB as chromogen. The primary antibody was rabbit
anti-Parvalbumin (Swant, PV27, 1:1000). Slides were fi-
nally counterstained with haematoxylin for 30 s to stain
cell nuclei. All staining was performed by investigators
blind to clinical diagnosis.
One section per case was analysed and PVþ cell den-
sities were generated using Stereo Investigator. Cortical
grey matter was outlined in each section and immune-
positive cells identified using an automated colour-based
thresholding algorithm. The accuracy of this automated
process was assessed on each section by manually check-
ing the identified objects. The number of immuno-positive
cells was expressed as a cell density by dividing the total
number by the total cortex area, expressed as PVþ cells/
mm2. All imaging and analysis were performed by inves-
tigators blind to clinical diagnosis.
Experimental design and statistical
analysis
Experimental data were analysed with the operator blind
to the genotype of animals. All statistical analyses were
conducted, and all figures plotted using Prism 8.3.0
(GraphPad Software, Inc.). All statistical comparisons are
based on biological replicates unless stated otherwise. All
charts show mean 6 SEM and statistical tests used
are described in the relevant results or figure legends.
P-values <0.05 were considered significant for all statis-
tical analyses used unless otherwise indicated.
Data availability
The datasets generated and/or analysed during the current




Regional parenchymal volume loss
and ventricular enlargement on
in vivo MRI
To identify structural brain changes caused by mutant
TDP-43Q331K we performed in vivo MRI on 7-month-old
male heterozygous (TDP-43Q331K/þ) and homozygous
(TDP-43Q331K/Q331K) mutant mice and wild-type litter-
mates. This represents an early symptomatic stage in this
model with evidence of executive dysfunction, but no
motor neuron loss.13 MRI revealed that the brain paren-
chymal volume decreased by 5.0% (Fig. 1A and B), with
homozygous mutants demonstrating a range of volumet-
ric changes, indicating phenotypic heterogeneity as previ-
ously described.13 Furthermore, there was a striking
49.7% increase in total ventricular volume in TDP-
43Q331K/Q331K mice compared to wild-types (Fig. 1C).
There was no significant difference in total brain and
ventricular volume combined (Fig. 1D). Furthermore,
voxelwise analysis using TBM19 revealed widespread stat-
istically significant (FWE P< 0.05) volume reductions in
cortical, subcortical and cerebellar regions in TDP-
43Q331K/Q331K compared to wild-type mice (Fig. 2A).
To more precisely define patterns of atrophy and iden-
tify brain areas most vulnerable to mutant TDP-43Q331K,
we conducted an ROI analysis using the DSURQE mouse
brain atlas. This allowed us to compare the volumes of
182 pre-defined regions between the groups of mice.
Fifty-one regions with statistically significant volume
changes between TDP-43Q331K/Q331K and wild-type mice
were identified after correction for multiple comparisons
at 5% false discovery rate (Table 1 and Fig. 2B). The
most significant cortical volume reductions occurred in
the frontal, motor, entorhinal, orbital and cingulate corti-
ces, while subcortical volume loss was most marked in
the nucleus accumbens, thalamus, subiculum, hippocam-
pus, basal forebrain and the brain stem. In the cerebel-
lum, there were decreases in the flocculus and the deep
nuclei (dentate and interpositus), as well as in the cere-
bro-cerebellar white matter tracts (cerebellar peduncles).
The most significant volume increase was, as expected, in
the lateral ventricles, although the volumes of the third
and fourth ventricles were not significantly affected while
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the cerebral aqueduct was decreased in size (Table 1).
We also detected apparent volume increases in several
grey and white matter ROIs, notably the CA3 hippocam-
pal field and fimbria. However, these are likely to be
artefacts caused by the proximity of these ROIs to the
enlarged lateral ventricles, which can cause signal con-
tamination due to partial volume effects, imperfect nor-
malization and smoothing used in tensor-based
morphometry analysis.25 This is illustrated in
Supplementary Fig. 1, which shows the ventricles of the
normalized subjects extending slightly beyond the ven-
tricle ROIs of the atlas; the image registration was other-
wise very good. Overall, the pattern of regional brain
volume reduction in TDP-43Q331K/Q331K mice was remin-
iscent of that seen in patients with ALS-FTD and in pre-
symptomatic carriers of ALS-FTD-linked gene mutations
(Table 1).
Comparison of heterozygous TDP-43Q331K/þ with wild-
type mice yielded no statistically significant volume differ-
ences after correction for multiple comparisons at 5% false
discovery rate. However, TDP-43Q331K/þ mice did
demonstrate trends towards volume loss or gain in several
brain regions that were significant in TDP-43Q331K/Q331K
mice (see Supplementary Fig. 2). This suggests a dose-effect
of the mutation on brain structural phenotypes. Indeed,
we made analogous observations in our previous study
with TDP-43Q331K/þ mice, which demonstrated similar be-
havioural and transcriptomic changes to those seen in
TDP-43Q331K/Q331K mice, but of smaller magnitude.13 We
therefore focused our attention on comparing wild-type
with TDP-43Q331K/Q331K mice in subsequent histological




We previously observed a reduced density of PVþ inter-
neurons as well as reduced PV mRNA expression at both
5 and 20 months of age in frontal cortices of TDP-
43Q331K/Q331K mice.13 Given that reduced PVþ neuron
density and a loss of other gamma-aminobutyric acid
Figure 1 In vivo MRI reveals global brain volume loss and ventricular enlargement in 7-month-old TDP-43Q331K/Q331K knock-in mice. (A)
Quantification of brain parenchyma volume. ANOVA P ¼ 0.0191. Pairwise comparisons: þ/þ versus Q331K/þ: ns P ¼ 0.1159; þ/þ versus
Q331K/Q331K: * P ¼ 0.0115. (B) Quantification of brain parenchyma volume as a percentage of total brain volume. ANOVA P < 0.0001.
Pairwise comparisons: þ/þ versus Q331K/þ: ns P ¼ 0.7448; þ/þ versus Q331K/Q331K: **** P < 0.0001. (C) Quantification of ventricle
volume. ANOVA P ¼ 0.0003. Pairwise comparisons: WT (þ/þ) and TDP43Q331K/þ (Q331K/þ): ns P ¼ 0.8597; WT (þ/þ) and TDP43Q331K/
Q331K (Q331K/Q331K): *** P ¼ 0.0004. (D) Quantification of brain parenchyma volume and ventricular volume combined. ANOVA
P ¼ 0.3405. (A–D) Each dot represents one mouse. Groups were compared by one-way ANOVA followed by Holm–Sidak post hoc test for
pairwise comparisons; error bars represent mean 6 SEM.
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(GABA)ergic inhibitory interneuron subtypes is also
observed in patients with ALS,55–57 we reasoned that
interneuron readouts could be a sensitive indicator of re-
gional brain vulnerability in ALS-FTD. We therefore
immunostained for PV and the GABA synthetic enzyme
glutamic acid decarboxylase 1 (GAD1/GAD67) in four
ROIs demonstrating volume loss on MRI. We also ana-
lysed PVþ interneuron density in the visual cortex as a
negative control as this area was largely unaffected on
MRI (Fig. 3A and B). We found that the frontal cortex
showed a reduction (by 27.1%) in PVþ interneuron
density in mutant mice. The cingulate cortex was one of
the most significantly affected subregions within the
frontal cortex, demonstrating a 50.1% reduction of PVþ
interneuron density. The entorhinal cortex and the den-
tate gyrus of the hippocampus demonstrated 60.2% and
39.8% reductions in PVþ interneuron density, respective-
ly. By contrast, there was no significant reduction in
PVþ interneuron density in the visual cortex. Finally, to
determine if other interneuron subtypes could be affected
by mutant TDP-43Q331K we quantified somatostatin-posi-
tive (SOMþ) interneurons. No significant change in
SOMþ interneuron density was seen in mutant mice (see
Supplementary Fig. 3A and B). We also examined overall
GAD expression but saw no significant change in GAD
expression in mutant mice (Supplementary Fig. 3C).
Collectively, these results indicate that PVþ interneurons
are selectively reduced in number in MRI regions that are
significantly reduced in volume, and this may correlate
with regions of volume loss on MRI.
Widespread microglial activation
Glial involvement in the pathogenesis of ALS-FTD is well
established, with both astrocytic and microglial activation
reported, while the presence of TDP-43 pathology in
white matter implicates oligodendrocytes as well.58–60 To
determine the responses of glia to mutant TDP-43Q331K,
we used immunohistochemistry to study two MRI-defined
brain ROIs, and again used the visual cortex as a
Figure 2 In vivo MRI reveals regional brain volume loss and ventricular enlargement in 7-month-old TDP-43Q331K/Q331K knock-
in mice. (A) A map of voxel-wise differences in volume between 7-month-old þ/þ and Q331K/Q331K mice calculated from in vivo MR images,
overlaid on the T1-weighted study-specific template. The map is displayed in the coronal plane (rostral-caudal) and the transverse plane (ventral–
dorsal). The R and L indicate the right and left sides of the mouse. The colours of the overlay indicate the percent volume difference (cool
colours indicate reduced volume in Q331K/Q331K mice compared to þ/þ mice), and the opacity of the overlay indicates the significance of the
volume difference (regions where the FWE-corrected P > 0.5 are completely transparent, and regions where the FWE-corrected P ¼ 0
completely opaque). Black contours demarcate regions where the FWE-corrected P < 0.05. (B) A similar map as in (A) but showing differences
in the DSURQE atlas ROI volumes. Black contours demarcate ROIs where the false discovery rate-corrected P < 0.05. ROIs of particular
interest are annotated.
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negative control region. Iba1 immunostaining revealed
significant increases in the area of staining and in micro-
glial density in the frontal and entorhinal cortices of
TDP-43Q331K/Q331K mice, while Tmem119 immunostain-
ing was significantly reduced in these regions (Fig. 4A–
D). Surprisingly, the visual cortex also displayed both
increased Iba1 and decreased Tmem119 staining.
Astrocytes, however, demonstrated no evidence of activa-
tion or proliferation in mutant mice by immunostaining
for glial fibrillary acidic protein (see Supplementary Fig.
4A and B). Immunostaining for myelin basic protein also
showed no significant difference between mutant and
wild-type mice, suggesting no change in myelination due
to mutant TDP-43Q331K (see Supplementary Fig. 4C and
D). Collectively, these results indicate that the earliest
glial change in TDP-43Q331K knock-in mice is the trans-
formation of microglia into a disease-associated state,
and that this occurs even in the absence of volume loss
on MRI.
Reduced hippocampal neurogenesis
Another region demonstrating significant volume loss on
MRI and reduced PVþ interneuron density was the hip-
pocampal dentate gyrus (DG). Given that this structure is
an important niche for adult hippocampal neurogenesis
(AHN) and that PVþ interneurons have an essential role
in neurogenesis,61,62 we quantified markers of cell prolif-
eration (Ki67) and immature neuron formation [double-
cortin (DCX)] in the granule cell layer of the DG. We
found no difference in the number of Ki67þ cells be-
tween wild-type and TDP-43Q331K/Q331K mice, suggesting
that the rate of progenitor cell division was unaffected
(Fig. 5A and B). However, quantification of DCXþ cells
revealed a significant reduction in the number of imma-
ture neurons in the granule cell layer of TDP-43Q331K/
Q331K mice (Fig. 5A and C). Given the volume changes in
the lateral ventricles we also examined the subventricular
zone, another key area of adult neurogenesis, but found
no evidence of impaired neurogenesis here (Fig. 5D–F).
Collectively, these results indicate that mutant TDP-
43Q331K reduces the number of progenitor cells under-
going neuronal differentiation or, alternatively, reduces
the number of cells surviving to the immature neuron
stage in the DG, and that a paucity of PVþ interneurons
could be contributing to this.
Aberrant neurodevelopment
One of the most striking observations on MRI was the
lateral ventricular enlargement in TDP-43Q331K/Q331K
mice. This could simply be secondary to a reduction in
the brain parenchyma, but another explanation is that
the ventricular system had not developed properly and
that the ventriculomegaly actually represents a state of
hydrocephalus. Indeed, the cerebral aqueduct was signifi-
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that cerebrospinal fluid outflow could be compromised.
Furthermore, occasional juvenile mutants demonstrated
frank hydrocephalus with doming of the skull and had to
be euthanized before 6 weeks of age (Fig. 6A and B). We
postulated that the ventricular enlargement of mutants
that survived through to later adulthood could also have
occurred early in life, before significant ossification of
cranial sutures, and that this would be reflected as a
change in skull shape that would persist into adulthood
once skull plates had fused. We therefore performed ex
vivo micro-CT on heads of aged 24-month-old male
mice. Indeed, geometric morphometric comparison of
TDP-43Q331K/Q331K and wild-type littermate skulls using
principal component analysis revealed a significant differ-
ence in shape between the two genotypes (Fig. 6C and
D). Specifically, a subtly dysmorphic craniofacial structure
was seen in mutants characterized by mid-facial hypopla-
sia and brachycephaly—effectively an increase in skull
sphericity—and a reduction in overall skull size (Fig. 6E).
These changes are in keeping with the hypothesis that
TDP-43Q331K disrupts the development of the ventricular
system.
We also wished to determine if mutant TDP-43Q331K
influenced the development of the brain parenchyma
itself. We therefore turned to our histological readout of
choice, PVþ interneuron density, looking specifically at
the hippocampi of juvenile P14 mouse pups (Fig. 7A).
We found a significant reduction of PVþ interneuron
density in the DG of mutant mice, particularly the hilus,
but no changes in the CA3 region (Fig. 7B–E). These
observations establish a role for TDP-43 in the develop-
ment of PVþ interneurons in the brain. This in turn sug-
gests that the paucity of PVþ interneurons in adult mice
is at least partly due to their failure to develop in the
first place.
Paucity of PV1 interneurons in
human ALS
Our MRI-guided histological survey in mutant mice indi-
cated a central role for PVþ interneurons in several
aspects of TDP-43Q331K-mediated disease: regional vulner-
ability of the brain, aberrant neurogenesis and neurode-
velopment. We therefore sought to determine if
disruption to PVþ interneurons was a feature of human
disease. We immunostained for PV in the dorsolateral
prefrontal cortex of 18 patients with ALS patients (6
with C9orf72 mutations and 12 sporadic ALS cases
A
B
Figure 3 Parvalbumin neuron density is reduced in MRI regions of interest in 7-month-old TDP-43Q331K/Q331K mice. (A)
Representative images showing parvalbumin (PV) staining, GAD67 staining, and DAPI (blue) in indicated regions of 7-month-old WT (þ/þ) and
TDP43Q331K/Q331K (Q331K/Q331K) mouse brains. (B) Quantification of PVþ interneuron density in given brain regions. Each dot represents
one mouse. Comparisons between WTand TDP43Q331K/Q331K as follows: frontal cortex * P ¼ 0.0186; cingulate cortex, * P ¼ 0.0107; entorhinal
cortex, ** P ¼ 0.0026; dentate gyrus, ** P ¼ 0.0074; visual cortex, P ¼ 0.4742 (ns, not significant). P-values were calculated with multiple t-tests
adjusted by Holm–Sidak correction. Error bars represent mean 6 SEM.
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without known ALS gene mutations) and 11 age and
sex-matched neurologically normal controls (Fig. 8A).
Demographic details of brain donors are given in
Supplementary Tables 2 and 3, including post-mortem
interval, sex, age and C9orf72 genetic status. There was
no significant effect of post-mortem interval or age on
PVþ interneuron density (Fig. 8B and C). However, we
detected a 24.6% reduction of PVþ interneuron density
in ALS patients relative to controls (Fig. 8A and D) with
both mutant C9orf72-linked ALS and sporadic ALS cases
showing a similar deficiency. This confirms that a paucity
of PVþ interneurons in the frontal cortex is a feature of
human ALS. Braak and Thal staging of the frontal cortex
of a subset of cases did not suggest that tau or amyloid
pathology was associated with PV neuron loss
(Supplementary Tables 2 and 3), though more studies are
needed to confirm this.
Discussion
Treatment for neurodegenerative diseases is likely to be
most effective during presymptomatic or prodromal
stages, and biomarkers sensitive to these periods are
needed. Preclinical models that accurately reflect human
disease are therefore essential, facilitating the discovery of
Figure 4 Global microglial activation in the TDP-43Q331K/Q331K mutant mouse brain. (A) Immunohistochemistry showing
microglia marker Iba-1 (green), Tmem119 (red) and DAPI (blue) in indicated regions of 7-month-old þ/þ and Q331K/Q331K mouse brains.
Scale bar, 20 lm. (B) Quantification of microglia density based on Iba-1 and DAPI immunoreactivity in given brain regions. Comparisons
between þ/þ and Q331K/Q331K as follows: frontal cortex, ** P ¼ 0.0028; entorhinal cortex, ** P ¼ 0.0012; visual cortex, * P ¼ 0.0113. (C)
Quantification of percentage area of Iba-1 in given brain regions. Comparisons between þ/þ and Q331K/Q331K: frontal cortex, ** P ¼
0.0043; entorhinal cortex, ** P ¼ 0.0035; visual cortex, * P ¼ 0.0107. (D) Quantification of percentage area of Tmem119 in given brain
regions. Comparisons between þ/þ and Q331K/Q331K: frontal cortex, ** P ¼ 0.0039; entorhinal cortex, * P ¼ 0.0174; visual cortex, * P ¼
0.0122. (B–D) Each dot represents one mouse. P-values were calculated with multiple t-tests adjusted by Holm–Sidak correction. Error bars
represent mean 6 SEM.
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molecular pathological changes underlying the very ear-
liest stages of disease. Here, using structural MRI, we
detected an extensive pattern of brain volume loss in
TDP-43Q331K knock-in mice, a preclinical model for ALS-
FTD, while still at an early stage of disease. Significantly,
many of the brain areas affected in mutant mice are
analogous to those involved in patients with FTD.63,64
Similar regions have also been implicated in recent studies
of patients with ALS.3 Perhaps most importantly, pre-
symptomatic carriers of ALS-FTD-linked gene mutations
also demonstrate atrophy in these brain areas, even deca-
des in advance of clinical onset.2,4,37 A detailed list of
affected mouse and human brain regions is given in
Table 1. Collectively, these observations underscore the
value of the TDP-43Q331K knock-in mouse in revealing
in vivo structural biomarkers relevant to the pathogenesis
of disease in patients with ALS-FTD.
Interestingly, our MRI studies of TDP-43Q331K mice
highlighted numerous regions beyond the frontal and tem-
poral lobes that have only recently also emerged as being
affected in patients. Thalamic regions were smaller in mu-
tant mice, mirroring observations in patients with sporadic
and familial FTD caused by mutations in C9orf72, MAPT
and GRN. The thalamus represents an important hub,
modulating the flow of information between the external
environment and the cortex, and could be contributing to
many facets of FTD including abnormalities of cognition,
attention and personality. The cerebellum was also affected
in mutant mice, and it has been shown that cerebellar at-
rophy occurs in both mutant C9orf72 and MAPT
Figure 5 Aberrant neurogenesis in TDP-43Q331K/Q331K mice. (A) Immunohistochemistry showing cell division marker Ki67 (arrow
heads) and immature neuron marker DCX in the mouse hippocampal dentate gyrus of 7-month-old þ/þ and Q331K/Q331K mice. Scale bar,
40 and 100 lm, representatively. (B) Quantification of Ki67þ cells per dental gyrus (DG) section in hippocampus between þ/þ and Q331K/
Q331K mice: ns P ¼ 0.9183. (C) Quantification of DCXþ cells per DG section in the hippocampal dentate gyrus between þ/þ and Q331K/
Q331K mice: *** P ¼ 0.0008. (D) Representative images showing cell division marker Ki67 (arrow heads) and immature neuron marker DCX
in the mouse subventricular zone with (E, F) quantification. Comparisons between þ/þ and Q331K/Q331K as follows: Ki67, ns P ¼ 0.8820;
DCX, ns P ¼ 0.1794. V ¼ lateral ventricle. (B, C, E, F) Each dot represents one mouse. Groups were compared by unpaired two-tailed t-
test. All data shown are mean 6 SEM.
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associated FTD.2 Furthermore, cerebellar integrity has been
associated with cognitive performance,52 while functional
MRI has identified impaired connectivity of cerebellar
regions with the cerebrum in FTD.65 Dysfunctional cere-
bellar and cortico-cerebellar circuits, particularly involving
the vermis and the deep nuclei, are recognized as core con-
tributors to psychosis, which can be part of the clinical
picture of FTD.66 Finally, the flocculus, which functions in
ocular motility, was also affected in mutant mice, and this
is notable as MRI changes in the cerebellum and eye
movement abnormalities can occur in patients with
ALS.67,68 More detailed studies of cerebellar changes in
TDP-43Q331K mice may help to unravel the role of this
intriguing brain structure in the symptomatology and
pathogenesis of ALS-FTD.
Enlargement of the lateral ventricles is also emerging as
a sensitive MRI biomarker in human FTD.25,54 This may
be due to subcortical parenchymal volume loss since one
of the imaging hallmarks of FTD, and a point of diver-
gence from Alzheimer’s disease (AD), appears to be
greater subcortical than cortical brain atrophy.69 It was
therefore remarkable that TDP-43Q331K mice also had
enlarged lateral ventricles. While this ventriculomegaly
could be due to loss of brain parenchyma, it could also
reflect hydrocephalus. In this respect, it is notable that
elderly patients with FTD and concomitant hydrocephalus
can show clinical improvement following cerebrospinal
fluid removal.70,71 Assaying cerebrospinal fluid pressure
in TDP-43Q331K mice would therefore be of interest.
Nonetheless, our observation that frank hydrocephalus
occurred in a small number of juvenile TDP-43Q331K
mice is enough to suggest that a developmental contribu-
tion towards ventricular enlargement in mutants is likely.
Corroborating this, our micro-CT analysis elucidated that
even aged TDP-43Q331K mice have more spherical skulls,
suggesting that intracranial pressure was raised prior to
skull plate fusion (i.e. during development). Although
skull shape changes can occur in humans in association
with age-related brain atrophy,72 we conclude that en-
largement of ventricles in TDP-43Q331K mice is at least
partly developmental in origin. A dedicated neuroimaging
study of younger mice with serial scans as they age
Figure 6 Altered skull shape in TDP-43Q331K/Q331K mice. (A) Photo of scalped head of a Q331K/Q331K mouse and (B) ex vivo MRI
scan of fixed head of the mouse. (C) Geometric morphometric analysis of þ/þ versus Q331K/Q331K mice. Average landmark configurations
of þ/þ and Q331K/Q331K skulls superimposed on þ/þ average skull, showing (clockwise from top left) lateral, superior, rear and inferior
views. Each dot represents a single standardized landmark, the colour indicating the average for each genotype. (D) Principal component
analysis (first two components) of skull shape variation after scaling. (E) Centroid sizes (the square root of the sum of the squared distances
of a set of landmarks from their collective centroid) of þ/þ and Q331K/Q331K skulls. Groups were compared by unpaired two-tailed t-test:
** P ¼ 0.0022. Error bars represent mean 6 SEM. (D, E) Each dot represents one mouse.
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would be of value to determine to what extent structural
changes are developmental or degenerative.
The recapitulation in TDP-43Q331K knock-in mice of
analogous brain MRI changes seen in prodromal human
ALS-FTD allowed us to address a fundamental question
in neurology: how do disturbances in ubiquitously
expressed proteins such as TDP-43 cause regionally se-
lective degeneration in the nervous system? We
approached this question by performing a histological
survey and found that TDP-43Q331K knock-in mice were
deficient in PVþ interneurons in areas showing atrophy
on MRI, but not in an area with no volume loss. While
this finding remains an association, it is notable that we
also found that PVþ interneurons are reduced in human
ALS frontal cortex. Previous studies of cortical
GABAergic interneurons in ALS have identified robust
reductions in calbindin D-28 immunoreactive cells in the
motor cortex,55,56 but analyses of PVþ interneuron num-
bers have been less conclusive. One study found a
significant decrease of PVþ interneurons in the motor
cortex but did not examine more anterior regions of the
brain,57 while another found only a trend towards a re-
duction in layer VI of the frontal cortex.56 A third study
found no decrease in PVþ interneurons in the frontal
cortex in two patients with ALS with dementia.55 Our
study more strongly points towards a reduction in PVþ
interneurons as being correlated with ALS and, further-
more, shows that both sALS and C9orf72-linked ALS
display a similar degree of loss. In theory, such a loss of
PVþ interneurons could lead to a reduction in cortical
inhibition, which could have excitotoxic consequences for
the pyramidal projection neurons onto which they syn-
apse.73 In support of this proposal, patients with muta-
tions in C9orf72, the most common genetic cause of ALS
and FTD, have been found to demonstrate cortical hyper-
excitability.74 Other mouse models of ALS have also
identified a reduction in PVþ interneurons, including
transgenic wild-type TDP-43 and SOD1G93A mice.75,76
Figure 7 Paucity of PV1 neurons in hippocampi of P14 TDP-43Q331K/Q331K mice. (A) Low magnification DAPI-stained overview of
mouse P14 hippocampal regions. Scale bar, 200 lm. (B) PVþ interneurons shown in given regions of the hippocampus in P14 þ/þ and
Q331K/Q331K mice. Scale bar, 50 lm. (C) Quantification of PVþ interneuron density in dentate gyrus (DG) comparing þ/þ to Q331K/
Q331K mice: * P ¼ 0.0142. (D) Of regions within DG, quantification of PVþ interneuron density in hilus comparing þ/þ to Q331K/Q331K
mice: * P ¼ 0.0315; granule cell layer (GCL): ns P ¼ 0.3133 and molecular layer (ML): ns P ¼ 0.1957. (E) Quantification of PVþ interneuron
density in C3 area: ns P ¼ 0.9061. (C, D) Each dot represents one mouse. P values were calculated with multiple t-tests adjusted by Holm–
Sidak correction. Error bars represent mean 6 SEM.
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Future studies should aim to determine whether the
reduced PV staining is due to a paucity of neurons or, al-
ternatively, a reduction in PV expression within a subset
of PV neurons (possibly due to a reduction in their activ-
ity). It will also be of value to determine if PV neuron
loss is seen more broadly in other genetic forms of ALS
and FTD. Further immunohistochemical studies of larger
cohorts of patients are needed. Nonetheless, aiming to
promote PVþ interneuron activity is worthy of further
study as a possible disease-modifying approach in neuro-
degenerative disease. The relevance of this approach
could be broad as PV neuron loss has been observed in
Huntington’s disease, Lewy body disease and Alzheimer’s
disease.77–79
Intriguingly, we also observed a paucity of PVþ inter-
neurons in P14 mice. This suggests that the deficiency of
these cells in adult mice may be because they did not de-
velop in the first place. Fast-spiking PVþ interneurons are
the main modulators of synaptic plasticity during the crit-
ical period of cortical development, and disruption of
interneurons leads to abnormalities in neuronal excitability,
a feature of neurodevelopmental disorders, such as autism
and schizophrenia.80–83 While ALS-FTD is not regarded as
a developmental disease, mutations in some ALS-causing
genes have been associated with juvenile-onset ALS with
learning difficulties and autism,84,85 and studies have sug-
gested that network degeneration in asymptomatic carriers
of C9orf72 mutations could be a consequence of aberrant
patterning during development.38 There is also growing
evidence of a genetic correlation between ALS and schizo-
phrenia, another disease of neurodevelopmental origin.86,87
In this respect, it is interesting to note that both autism
and schizophrenia demonstrate a paucity of PVþ inter-
neurons.83 Thus, it is not inconceivable that disturbances
in cortical excitation–inhibition balance during develop-
ment may later predispose an individual to developing an
age-related neurodegenerative disease. More studies are
needed to map the migration and proliferation of embry-
onic PV neurons to determine to what extent their paucity
in the adult mouse brain is developmental or degenerative.
Human derived brain organoids could be a useful ap-
proach to validate in man.
Another important role served by PVþ interneurons is
that of promoting hippocampal neurogenesis in the adult
brain.62 We were therefore intrigued by the observation
that the DG of the hippocampus, a niche for AHN, was
smaller in TDP-43Q331K mice and demonstrated a signifi-
cant loss of PVþ interneurons. Examination of the number
of immature neurons suggested that AHN was impaired in
mutant mice. An alternative intriguing notion is the possi-
bility that the reduction in DCX neurons is due to acceler-
ated maturation as a compensatory response to neuronal
loss. Validation with birth-dating techniques (e.g. using
thymidine analogues such as BrdU or EdU) used in paral-
lel with markers of neurons (NeuN) would be helpful to
confirm a role for TDP-43 in neurogenesis.
Figure 8 Paucity of PV1 neurons in DLPFC of ALS patients. (A) Immunohistochemistry showing PVþ interneurons in the
dorsolateral prefrontal cortex (DLPFC) of neurologically healthy controls and ALS patients. Scale bar, 300 lm. (B) Scatter plot demonstrating
PVþ interneuron density versus post mortem interval for each case (cases and controls combined). (C) Scatter plot demonstrating PVþ
interneuron density versus age of each patient (cases and controls combined). D Quantification of PVþ interneuron density (cells/mm2) in
DLPFC: * P ¼ 0.0447. Each dot represents one case. Groups were compared by unpaired two-tailed t-test: Error bars represent mean 6
SEM.
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While AHN has been shown to be impaired in
AD,88,89 neurogenesis has been little studied in ALS-FTD.
Interestingly, however, one human post-mortem study
identified a reduction in the proliferation of neural pro-
genitor cells in the hippocampi of patients with ALS.90
Furthermore, overexpression of TDP-43 in neural pro-
genitor cells of the developing mouse telencephalon was
found to impair neurogenesis,91 while knockdown of
TDP-43 in vitro resulted in increased expression of neu-
rogenin 2, a transcription factor that specifies neuronal
fate during development.92 Our study adds to this litera-
ture by demonstrating an in vivo role for TDP-43 in
neurogenesis within the adult brain. Given the importance
of adult-born hippocampal neurons to spatial memory,
pattern separation, mood and cognition,93,94 impaired
AHN due to TDP-43 misregulation may well have con-
tributed to the behavioural phenotypes we previously
described in mutant mice.13 Further studies to delineate
the link between PVþ interneurons and AHN are war-
ranted as we speculate that this will help find ways to le-
verage the neurogenic potential of the brain for
therapeutic benefit in ALS-FTD.
In our analysis of non-neuronal cells we noted that
microglia were in an activated state in TDP-43Q331K
knock-in mice. Microglia are thought to have a ‘survey-
ing’ role when quiescent and become activated in neuro-
degenerative diseases, engulfing cellular debris,
phagocytosing protein aggregates and pruning synapses,
possibly through complement activation.95–97 Using indu-
cible TDP-43 transgenic mice, it has been shown that
microglia play a key role in recovery from neurodegener-
ation.98 Unexpectedly, we found that microglial activation
occurred even in the visual cortex, an area that was
largely unaffected on MRI and which was not deficient
in PVþ interneurons. This suggests that microglial activa-
tion is widespread and does not explain regional brain
vulnerability in TDP-43Q331K knock-in mice, at least
when 7 months old. This also raises the intriguing possi-
bility that microglial activation precedes and therefore
may cause neuronal loss. Although activated microglia in
the mouse brain is regionally and functionally heteroge-
neous, and they may not be acting destructively, the
reduced Tmem119 we observed is indicative of a shift to
a DAM phenotype in mutants. This prompted us to re-
examine our previous RNASeq analysis of frontal cortical
tissue from 5- to 20-month-old mice13 (Supplementary
Table 4). Looking specifically for microglial and micro-
glia-related genes that were differentially expressed be-
tween wild-type and homozygous mutant mice, we
confirmed that Iba1 gene expression was increased.
Intriguingly, Tmem119 gene expression was downregu-
lated in mutants, which contrasts with the increase in
Tmem119 protein that we found with immunohistochem-
istry. This dissociation between Tmem119 transcript and
protein levels has been noted before in the context of
activated microglia.18 Further, work should therefore be
directed at examining how protein translation is altered
in activated microglia as well as more detailed analyses
of microglial morphology in TDP-43Q331K mutant mice.
Conclusions
In conclusion, MRI changes in human ALS-FTD are reca-
pitulated in TDP-43Q331K knock-in mice, allowing this
model to be used to understand the cellular and molecular
meaning of early macroscopic brain changes, something
that is currently impossible in humans. Further studies of
TDP-43Q331K knock-in mice (including female mice) using
longitudinal structural and functional MRI and MR spec-
troscopy promise to help delineate the natural history of
ALS-FTD, and the role of neurodevelopmental abnormal-
ities in disease. More detailed examination of molecular
changes within affected and unaffected brain regions, for
example using in situ transcriptomic approaches, should
help to unravel how different neuronal and glial subtypes
contribute to disease, including during development and in
neurogenic niches. This approach, in quantifying TARDBP
transcript levels, may also help to determine the extent to
which TDP-43 expression level correlates with volume
loss. These profiles will ultimately be of value in measur-
ing the efficacy of therapeutic approaches designed to treat
and perhaps even prevent ALS-FTD.
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online.
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